Hengrui secures clinical trial approval for dermatitis treatment

Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiary, Guangdong Hengrui Pharmaceutical Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for SHR-1905 injection. The drug, designated for atopic dermatitis, is a thymic stromal lymphopoietin (TSLP) monoclonal antibody designed to block inflammatory cytokines and control disease progression.

The approval, granted on July 17, 2025, allows the company to initiate clinical trials for SHR-1905 injection. The announcement highlights that current global sales for a similar product, Tezepelumab (marketed as Tezspire by AstraZeneca/Amgen), are approximately $1.22 bn as of 2024.

As of the announcement date, cumulative research and development investment for SHR-1905 injection totals approximately 20,962 yuan. The company cautioned investors about the inherent risks associated with drug development, including lengthy timelines and uncertain outcomes from clinical trials through to market approval.